论文部分内容阅读
目的:探讨甲基泼尼松龙对急性脑衰竭的治疗作用。方法;对入选的72例急性脑衰竭病人随机对照研究,甲基泼尼松龙组和对照组病人各36例。根据Glasgow-Pittsberg昏迷评分,对两组病人治疗前及治疗后7、14天的临床神经功能状况进行比较,评定临床效果。对比观察两组病人病死率及副作用发生情况。结果:治疗第7天甲基泼尼松龙组的昏迷评分明显高于对照组(P<0.05);甲基泼尼松龙对于全身性疾病所致的急性脑衰竭疗效显著优于颅内疾病所致者(P<0.001)。结论:甲基泼尼松龙对急性脑衰竭有显著治疗作用。
Objective: To investigate the therapeutic effect of methylprednisolone on acute cerebral failure. Methods: A randomized controlled study of 72 patients with acute cerebral failure was enrolled. Thirty-six patients in the methylprednisolone group and the control group were enrolled in this study. According to the Glasgow-Pittsberg coma score, the clinical neurological status of the two groups of patients before treatment and after treatment for 7 and 14 days were compared to evaluate the clinical effect. Compare the two groups of patients mortality and side effects. Results: The coma score of methylprednisolone group on the 7th day of treatment was significantly higher than that of the control group (P <0.05). Methylprednisolone was superior to the intracranial disease in the treatment of acute cerebral failure caused by systemic diseases (P <0.001). Conclusion: Methylprednisolone has a significant therapeutic effect on acute cerebral failure.